Clinical Thyroidology® for the Public

Summaries for the Public from recent articles in Clinical Thyroidology
Table of Contents | PDF File for Saving and Printing

HYPOTHYROIDISM
Does starting levothyroxine treatment in older adults with subclinical hypothyroidism help their heart?

Instagram Youtube LinkedIn Facebook X

 

BACKGROUND
Hypothyroidism is common and is diagnosed with increased TSH and low FT4 levels. This is called overt hypothyroidism and is usually treated with thyroid hormone in the form of levothyroxine. Mild, or subclinical hypothyroidism, is diagnosed when the TSH is increased but the FT4 is normal. Treating subclinical hypothyroidism is not as clear. Subclinical hypothyroidism affects up to 20% of adults, being more common in women and older individuals.

The association between heart disease and subclinical hypothyroidism in older adults remains unclear. It is challenging to conduct studies that directly investigate whether patients with subclinical hypothyroidism have a higher risk of developing heart problems, since a large number of patients would need to be followed over many years. Cardiometabolic biomarkers, such as the cholesterol levels, may serve as a sensitive indicator of heart disease, as changes in these parameters could predict long-term clinical risk of heart disease. Several studies suggest that subclinical hypothyroidism is associated with increases in several cardiometabolic biomarkers, including elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein (ApoB), and triglycerides (TG). However, findings remain inconsistent. Further, evidence on the effects of levothyroxine treatment in subclinical hypothyroidism on these cardiometabolic biomarkers in older adults is limited.

The aim of this study was to evaluate the effects of levothyroxine on cardiometabolic biomarkers in older adults with subclinical hypothyroidism.

THE FULL ARTICLE TITLE
Ao L, Noordam R, Trompet S, et al. Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism. J Clin Endocrinol Metab 2026;111(9):2445–2455; doi: 10.1210/clinem/ dgag155. PMID: 41965091.

SUMMARY OF THE STUDY
This study pooled data from two large studies conducted in Europe: TRUST (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial) and IEMO80+ (Institute for Evidence-Based Medicine in Old Age 80-Plus Thyroid Trial). Both studies included older adults with subclinical hypothyroidism (TSH 4.6–19.9 mIU/L and normal free T4) who were 65 years or older (TRUST) or 80 years or older (IEMO80+). Patients were assigned either the levothyroxine treatment or no levothyroxine group. The levothyroxine dose was progressively increased as needed every 6-8 weeks based on blood TSH levels, with the goal to normalize the TSH. Patients were followed for 12 months and had blood collected at the beginning and end of the study to measure cardiometabolic biomarkers.

A total of 286 participants (48% women, average age 75 years, average baseline TSH 6.4 mIU/L) were randomized to levothyroxine (142 patients) or no levothyroxine (144 patients). Overall, the levothyroxine treatment showed no significant improvement in cardiometabolic biomarkers in this patient population. However, further subgroup analysis indicated that participants with more severe subclinical hypothyroidism (baseline TSH ≥10 mIU/L) treated with levothyroxine had potentially beneficial reductions in most cardiometabolic biomarkers, including Total-C, LDL-C, apoB, and TG. Similarly, further analysis showed potentially favorable reductions in apoBcontaining lipoproteins (LDL and very low-density lipoprotein/VLDL), as well as other cardiometabolic biomarkers, with levothyroxine treatment in patients with a baseline TSH ≥10 mIU/L.

WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This evaluation of two large clinical trials showed that levothyroxine treatment has no significant effect overall on cholesterol levels and other cardiometabolic biomarkers in the general older adult population with subclinical hypothyroidism. Potentially favorable changes were noted only in patients with a baseline TSH ≥10 mIU/L; however, these changes were small and of uncertain clinical effect. The study findings support current clinical guidelines recommending that treatment decisions in older adults with subclinical hypothyroidism should be individualized based on baseline TSH levels. Further larger clinical trials are needed to confirm the potential benefits in patients with a baseline TSH ≥10 mIU/L.

—Elie Naous, MD, Alina Gavrila, MD, MMSC

ABBREVIATIONS & DEFINITIONS

Hypothyroidism: a condition where the thyroid gland is underactive and doesn’t produce enough thyroid hormone. Treatment requires taking thyroid hormone pills.

Subclinical Hypothyroidism: a mild form of hypothyroidism where the only abnormal hormone level is an increased TSH. There is controversy as to whether this should be treated or not.

Thyroid stimulating hormone (TSH): hormone produced by the pituitary gland that regulates thyroid function; also, the best screening test to determine if the thyroid is functioning normally.

Levothyroxine (T4): the major hormone produced by the thyroid gland and available in pill form as Synthroid™, Levoxyl™, Tyrosint™ and generic preparations. Patients with hypothyroidism are most often treated with Levothyroxine in order to return their thyroid hormone levels to normal.

Lipids: the general term used to describe fat molecules in the blood. Examples of blood lipids include cholesterol, HDL (“good) cholesterol, LDL (“bad”) cholesterol, and triglycerides.

LDL-C: low density lipoprotein cholesterol, the type of cholesterol that has been associated with atherosclerosis and heart disease.